Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiovascular Diseases AND Heart Diseases AND Inflammation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    99 result(s) found for: Cardiovascular Diseases AND Heart Diseases AND Inflammation. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2009-017242-30 Sponsor Protocol Number: D5132C00001 Start Date*: 2010-12-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Sali...
    Medical condition: Myocardial Infarction, Cardiovascular Death, Atherothombosis, Stroke
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) DE (Completed) HU (Completed) RO (Completed) CZ (Completed) SK (Completed) PL (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed) NO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002106-13 Sponsor Protocol Number: ATH3G10-005 Start Date*: 2017-09-06
    Sponsor Name:Athera Biotechnologies AB
    Full Title: Double-blind, randomised, placebo-controlled, multicentre, Phase IIa study to investigate the effect of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together ...
    Medical condition: Arterial inflammation in subjects with elevated lipoprotein a (Lp[a])
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022953 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002455-26 Sponsor Protocol Number: IRON-CMR Start Date*: 2014-09-20
    Sponsor Name:Karolinska Institute
    Full Title: The use of intravenous Iron oxide as a contrast agent for cardiac magnetic resonance imaging.
    Medical condition: Cardiovascular diseases: Acute myocardial infarction, chronic myocardial infarction, myocardial ischemia, myocarditis, diffuse myocardial fibrosis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004853-59 Sponsor Protocol Number: EX6018-4758 Start Date*: 2021-08-16
    Sponsor Name:Novo Nordisk A/S
    Full Title: ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
    Medical condition: Atherosclerotic cardiovascular disease Chronic kidney disease Systemic inflammation
    Disease: Version SOC Term Classification Code Term Level
    26.0 10047065 - Vascular disorders 10051615 Atherosclerotic cardiovascular disease LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.1 10022891 - Investigations 10067394 hs-CRP increased LLT
    21.0 10022891 - Investigations 10011418 CRP increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) SK (Trial now transitioned) DE (Trial now transitioned) NL (Ongoing) SE (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002860-19 Sponsor Protocol Number: 2012 Start Date*: 2014-01-07
    Sponsor Name:AMC
    Full Title: The risk of cardiovascular disease in Ankylosing Spondylitis; A Single Center Cross-Sectional Study Evaluating The Association Between Inflammation In Ankylosing Spondylitis And Vascular Inflammati...
    Medical condition: Ankylosing Spondylitis Atherosclerotic cardiovascular disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001989-15 Sponsor Protocol Number: HomRate04_2012 Start Date*: 2012-09-17
    Sponsor Name:Universität des Saarlandes
    Full Title: A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiff...
    Medical condition: Stable coronary heart disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000201-24 Sponsor Protocol Number: O3Cardio Start Date*: 2018-08-01
    Sponsor Name:Bernardino Clavo - Hospital Dr. Negrín
    Full Title: Effectiveness and cost-effectiveness of Ozone therapy in patients with ischemic heart disease refractory to medical and surgical treatment: Randomized, triple-blind clinical trial.
    Medical condition: Ischemic heart disease refractory to medical and surgical treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    20.0 100000004849 10055224 Cardiac ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000233-73 Sponsor Protocol Number: HCQvJan11 Start Date*: 2016-01-05
    Sponsor Name:Helsinki University Central Hospital
    Full Title: HYDROXYCHLOROQUINE IN ACUTE CORONARY SYNDROME: PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS
    Medical condition: Cardiovascular disease
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005855-35 Sponsor Protocol Number: U1111-1270-0943 Start Date*: 2023-01-10
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascu...
    Medical condition: Atherosclerotic cardiovascular disease and Obesity
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) NL (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003179-12 Sponsor Protocol Number: MN0511_1 Start Date*: 2012-01-09
    Sponsor Name:University Hospital of Wuerzburg, Medical Director
    Full Title: Mineralocorticoid Receptor antagonists in End stage reNal DiseAse
    Medical condition: Hemodialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003406-10 Sponsor Protocol Number: BC21144 Start Date*: 2007-12-13
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A Phase IIb, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Ar...
    Medical condition: Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013317 Lipid metabolism disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) DE (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001319-38 Sponsor Protocol Number: MW051 Start Date*: 2015-09-24
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Monocenter prospective open single-arm phase IV study of the effects of hawthorn extract WS® 1442 on arterial micro-vascular structure and macro-vascular function, persistance and erectile functio...
    Medical condition: Underlying cardiovascular disease
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002628-29 Sponsor Protocol Number: R&D6327 Start Date*: 2014-09-09
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Evaluating the effectiveness of intravenous ciclosporin on reducing reperfusion injury in patients undergoing primary percutaneous coronary intervention: a double-blind, phase II, randomised contro...
    Medical condition: Myocardial ischemia/reperfusion injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001685-33 Sponsor Protocol Number: 07-002 Start Date*: 2007-12-28
    Sponsor Name:RWTH Aachen University
    Full Title: Prospective Comparison of Phenpocoumon (Marcumar) and Acetylsalicylic Acid (ASS) as to Progression of the Valvular and Coronary Calcification.
    Medical condition: Treatment with oral anti-coagulants prevents thromboembolic complications e.g at atrial fibrillation or artificial heart valves. Primary objective of the study is the prospective comparison of the ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002799-42 Sponsor Protocol Number: CAPstatin2013 Start Date*: 2014-03-27
    Sponsor Name:Dipartimento di Medicina Interna e Specialità Mediche - Policlinico Umberto I - Sapienza Università di Roma
    Full Title: Statins in the prevention of myocardial damage in pneumonia
    Medical condition: Patients hospitalized with community-acquired pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001604-17 Sponsor Protocol Number: APHP220428 Start Date*: 2022-11-15
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers
    Medical condition: Patients With Acute Heart Failure and Elevated Inflammatory Markers in Emergency Department
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005032-42 Sponsor Protocol Number: 17-162 Start Date*: 2020-04-20
    Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty
    Full Title: Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease
    Medical condition: Diabetes Type 2 with existing cardiovascular disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003105-25 Sponsor Protocol Number: MiLe-1 Start Date*: 2014-08-27
    Sponsor Name:Sahlgrenska University Hospital / The Queen Silvia Children´s Hospital
    Full Title: The prophylactic effect of levosimendan in reducing acute kidney injury postoperatively in pediatric patients undergoing corrective heart surgery
    Medical condition: Acute kidney injury postoperatively in connection with surgery for congenital heart disease
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006123-37 Sponsor Protocol Number: SI-C-019 Start Date*: 2012-06-06
    Sponsor Name:Solvotrin Innovations Ltd
    Full Title: Impact of Eplerenone on Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetic Patients
    Medical condition: Asymptomatic left ventricular diastolic dysfunction in diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.0 10007541 - Cardiac disorders 10052337 Diastolic dysfunction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000752-20 Sponsor Protocol Number: PETSPA Start Date*: 2015-06-29
    Sponsor Name:University of Helsinki
    Full Title: The efficacy of adalimumab and conventional antirheumatic drugs in alleviating axial and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis
    Medical condition: Axial and aortic inflammation detected in PET/CT imaging in patients with axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 06:51:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA